Please assess the completion status of the following clinical trial:

Trial Title: Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of seropositive (i.e., presence of RF and/or anti-CCP antibodies) rheumatoid arthritis (RA) according to the ACR/EULAR 2010 criteria within 24 months.~2. No previous treatment with disease modifying anti-rheumatic drugs (DMARDs). History of prednisone use is allowed but should have been discontinued 2 weeks before baseline measurement.~3. Active disease with ≥2 painful and ≥2 swollen joints in 66/68 joints and CRP ≥2.0 mg/L~4. Aged 18-80 years~5. The subject has given written consent to participate in the study.~Exclusion Criteria:~1. Current active inflammatory joint disease other than RA.~2. Significant and/or uncontrolled cardiac, pulmonary disease, nervous system, renal, hepatic, endocrine or gastrointestinal disorders or severe RA which in the investigator's opinion would preclude patient participation.~3. Malignancy within the past 5 years, except for successfully treated cervical carcinoma in situ, basal cell and squamous cell carcinoma of the skin, with no evidence of recurrence or metastatic disease for at least 3 years.~4. Primary or secondary immunodeficiency (history of, or currently active), including known history of HIV infection.~5. Pregnant or lactating women.~   For subjects in part II the following exclusion criteria also apply:~6. Women of childbearing potential not willing or able to use highly effective methods of birth control per ICH M3 (R2) for 28 days prior and 3 months after end of study.~7. Active infection (excluding fungal infections of nail beds) requiring i.v. anti-infectives within 4 weeks, or oral anti-infectives within 2 weeks prior to baseline.~8. Positive tests for hepatitis B (HBsAg or HBV DNA),hepatitis C serology or SARS-CoV2~9. History of herpes zoster infection during last 10 years.~10. History or risk of venous thromboembolism or diverticulitis.~11. Positive tuberculosis history and/or positive Quantiferon test.~12. Hemoglobin \<90 g/L.~13. Absolute neutrophil count \< 1500 cells/uL.~14. ASAT or ALAT \>2.0 times the upper limit of normal.~15. High or very high risk (≥ 5%) of cardiovascular death within 10 years by SCOREx1,5.~16. Multiple incidental solid/subsolid lung nodules of size ≥6 mm, single incidental solid lung nodules ≥8 mm.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Type: EXPERIMENTAL): Oral tablet tofacitinib 5 mg BID for 48 weeks
- Methotrexate (Type: ACTIVE_COMPARATOR): Oral tablet methotrexate 2.5 mg: 8 tablets in one dose (=20 mg) once weekly for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).